MedTrace Logo

Study of Tremelimumab in Patients With Advanced Solid Tumors

NCT02527434 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-11-15

Study results available
· View outcomes & findings →

Summary

A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors

Conditions

Interventions

BIOLOGICAL

Tremelimumab monotherapy

IV infusion

BIOLOGICAL

MEDI4736 monotherapy

IV infusion

BIOLOGICAL

MEDI4736 + tremelimumab combination therapy

IV infusion

Sponsors & Collaborators

Principal Investigators

  • Sharma Padmanee, MD, PhD · Anderson Cancer Center, the University of Texas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
150 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-02
Primary Completion
2018-02-17
Completion
2023-03-28
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Netherlands
  • Poland
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02527434 on ClinicalTrials.gov